Pfizer will start testing its coronavirus vaccine on children as young as 12, a crucial step to bringing the shot to more people



a woman in glasses looking at the camera: Steve Parsons-WPA Pool/Getty Images


© Steve Parsons-WPA Pool/Getty Images
Steve Parsons-WPA Pool/Getty Images

  • Pfizer is expanding its massive coronavirus vaccine clinical trial, opening the study to include children as young as 12.
  • The company is poised to become the first major drugmaker to start testing a COVID-19 shot in kids in a large-scale study.
  • The New York pharma giant said it got permission to boost the study’s overall size to as many as 48,400 volunteers.
  • Pfizer broadened the study last month to include 16- and 17-year-olds as well as people with HIV, hepatitis B, or hepatitis C. 
  • While early clinical results were promising, it remains to be seen if Pfizer’s vaccine — or any other experimental shot — can prevent COVID-19.
  • Pfizer CEO Albert Bourla has said he expects data from this study before the end of October. 
  • Visit Business Insider’s homepage for more stories.

Pfizer is setting plans to make its coronavirus vaccine

Read More

Trump’s children brought Secret Service money to the family business with their visits, records show

On trips like these, Secret Service agents were there to protect Trump’s children. But, for the Trump family business, their visits also brought a hidden side benefit.

That’s because when Trump’s adult children visited Trump properties, Trump’s company charged the Secret Service for agents to come along. The president’s company billed the U.S. government hundreds, or thousands, of dollars for rooms agents used on each trip, as the agency sometimes booked multiple rooms or a multiroom rental cottage on the property

In this way, Trump’s adult children and their families have caused the U.S. government to spend at least $238,000 at Trump properties so far, according to Secret Service records obtained by The Washington Post.

Government ethics experts say that nothing is wrong with Trump’s children seeking protection from the Secret Service.

But, they said, the Trump Organization’s decision to charge for the agents’ rooms created a situation in which

Read More

In Yemen, children begin classes in the ruins of war

Oct 9, 2020

With its walls pounded by artillery, roofs torn open and concrete beams in shreds, Al-Wehdah school lies in ruins as students return for the first day of Yemen’s school year.

At the school near Taez, the third-biggest city in a country shattered by years of war between the government and Iran-backed Huthi rebels, there are no doors or windows, let alone desks.

Instead the students use old exercise books to jot down their lessons, as they sit in makeshift classrooms with a handful of teachers brave enough to join them under crumbling ceilings.

Yet in a country where nearly a third of children don’t go to school at all, these are the lucky ones.

Al-Wehdah sc

hool was hit in a 2016 air strike.

Ali Sultan, a parent of one of the students, points out to AFP a warning sign in red letters written on a perimeter

Read More

Business lessons I learned from my children during lockdown

  • Petra Smith is the founder and managing director at Squirrels&Bears, a London-based marketing agency, and a mother of two.
  • Kids can teach us a lot about being successful in business, and in life, Smith said.
  • In an interview with Business Insider, Smith revealed the lessons she has learnt during the COVID-19 lockdown from her two and four years old children including being creative, ready to adapt, and the importance of taking care of your employees, clients and suppliers.
  • Visit Business Insider’s homepage for more stories.

When the COVID-19 lockdown hit, my children were just under two and four years old. Since they were born, they’ve been a source of inspiration and learning — about myself, my career, and family life. At seven months pregnant with my oldest daughter, I started my own business, and as our family grew, so did my business.

However, the impact of the pandemic has been

Read More

Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

NEW YORK & MIAMI–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency (GHD), met its primary endpoint of improved treatment burden compared to GENOTROPIN® (somatropin) for injection administered once-daily.

Top-line results from the study demonstrated that treatment with somatrogon once-weekly improved the mean overall Life Interference total score after 12 weeks of treatment (8.63) compared to treatment with somatropin administered once-daily (24.13). The point estimate of the treatment difference was -15.49 (-19.71, -11.27 (95% CI); p<0.0001) in favor of somatrogon at the nominal 0.05 level. In addition, key secondary endpoints showed an overall benefit in treatment experience with the somatrogon once-weekly dosing regimen compared to the somatropin once-daily dosing regimen.

“We’re encouraged by findings to date that

Read More